Vol. 1Sanqing’s Rise
Wei Kang transformed Sanqing Pharmaceutical with breakthrough cancer and Alzheimer’s drugs, expanding the company while confronting corporate obstruction and building new businesses. The volume ended with Sanqing launching its Alzheimer’s drug as families worried about whether they could afford it.
- Wei Kang used the Primary Pharmaceutical System to develop an anti-cancer drug, proved its effectiveness in clinical trials, and attracted international partnership offers while refusing to sell Sanqing or its formula.
- Wei Kang rejected acquisition offers and favored Pfizer’s licensing terms, asking prospective partners to provide abandoned drug formulas and safety data.
- Wei Kang signed a $3 billion overseas licensing deal with Pfizer, expanded Sanqing’s businesses, and helped bring its anti-cancer drug to patients despite regulatory obstruction.
- Wei Kang negotiated affordable domestic insurance prices with Chen Linghui, and the teams began discussing procurement.
- Wei Kang expanded Sanqing’s facilities and product lines as its cancer drug, hangover medicine, and beauty products gained attention.
- Wei Kang hired Wenren Long to lead research and help establish an AI Lab for medicinal chemistry.
- Wei Kang and Chen Yiqing developed Sanqing’s Alzheimer’s drug, whose clinical results drew worldwide attention despite a smear campaign and pressure from Pfizer executives.
- Sanqing pursued overseas markets independently, announced the drug’s Phase III results and release date, and launched it as families worried about its cost.